文献速递血栓与止血

儿童免疫性血小板减少症二线治疗选择中的医生决策

Physician decision making in selection of second-line treatments in immune thrombocytopenia in children.
PubMed 文献 · Am J Hematol · 2018-05-06

ICON1是一项前瞻性观察性纵向队列研究,纳入北美21个中心120例开始二线治疗的免疫性血小板减少症(ITP)患儿,由治疗医生报告选择治疗的理由并排序前三。倾向加权模型显示,患者/家长偏好(53%)及治疗相关因素如副作用(58%)、长期毒性(54%)、给药便利性(46%)、缓解可能性(45%)和感知疗效(30%)最重要;医生、卫生系统和临床因素很少影响决策。

要点

  • 患者/家长偏好是二线治疗选择的重要原因,慢性ITP(85.7%)高于新诊断(0%)和持续性ITP(14.3%,P = .003)。
  • 脾切除术和利妥昔单抗因可能诱导长期缓解而被选择(P < .001)。
  • 口服药物如艾曲泊帕和免疫抑制剂因给药便利性和预期依从性被选择(P < .001)。

核心结论

  • 在缺乏对照试验的情况下,儿童ITP二线治疗选择涉及复杂且多因素参与的决策过程。
  • 研究强调共享决策以及需要设计良好的比较有效性研究,以促进患者与临床医生之间的知情讨论。

研究设计与样本

  • ICON1是北美儿童ITP联盟(ICON)内开展的前瞻性、观察性、纵向队列研究。
  • 研究纳入来自21个中心的120例开始二线治疗的ITP患儿,由治疗医生报告选择治疗的理由并排序前三。

主要发现

  • 在倾向加权模型中,患者/家长偏好占53%,副作用谱占58%,长期毒性占54%,给药便利性占46%,缓解可能性占45%,感知疗效占30%。
  • 医生、卫生系统和临床因素很少影响决策。
  • 患者/家长偏好作为理由在慢性ITP中占85.7%,高于新诊断ITP的0%和持续性ITP的14.3%(P = .003)。
  • 脾切除术和利妥昔单抗因可能诱导长期缓解而被选择(P < .001)。
  • 口服药物如艾曲泊帕和免疫抑制剂因给药便利性和预期依从性被选择(P < .001);医生对预期依从性较低的患者选择利妥昔单抗(P = .017)。

关键数值与推荐

  • 患者/家长偏好:慢性ITP 85.7% vs 新诊断ITP 0% vs 持续性ITP 14.3%(P = .003)。
  • 脾切除术和利妥昔单抗因可能诱导长期缓解而被选择(P < .001)。
  • 口服药物如艾曲泊帕和免疫抑制剂因给药便利性和预期依从性而被选择(P < .001)。
  • 医生对预期依从性较低的患者选择利妥昔单抗(P = .017)。
  • 治疗选择显示一些医生和治疗中心偏倚。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder which presents with isolated thrombocytopenia and risk of hemorrhage. While most children with ITP promptly recover with or without drug therapy, ITP is persistent or chronic in others. When needed, how to select second-line therapies is not clear. ICON1, conducted within the Pediatric ITP Consortium of North America (ICON), is a prospective, observational, longitudinal cohort study of 120 children from 21 centers starting second-line treatments for ITP which examined treatment decisions. Treating physicians reported reasons for selecting therapies, ranking the top three. In a propensity weighted model, the most important factors were patient/parental preference (53%) and treatment-related factors: side effect profile (58%), long-term toxicity (54%), ease of administration (46%), possibility of remission (45%), and perceived efficacy (30%). Physician, health system, and clinical factors rarely influenced decision-making. Patient/parent preferences were selected as reasons more often in chronic ITP (85.7%) than in newly diagnosed (0%) or persistent ITP (14.3%, P = .003). Splenectomy and rituximab were chosen for the possibility of inducing long-term remission (P < .001). Oral agents, such as eltrombopag and immunosuppressants, were chosen for ease of administration and expected adherence (P < .001). Physicians chose rituximab in patients with lower expected adherence (P = .017). Treatment choice showed some physician and treatment center bias. This study illustrates the complexity and many factors involved in decision-making in selecting second-line ITP treatments, given the absence of comparative trials. It highlights shared decision-making and the need for well-conducted, comparative effectiveness studies to allow for informed discussion between patients and clinicians.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Grace RF, Despotovic JM, Bennett CM, et al. Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. Am J Hematol. 2018. PMID: 29659042. doi:10.1002/ajh.25110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。